A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors

OBJECTIVE: To investigate the clinical efficacy and safety of anlotinib combined with anti-PD-1 inhibitors in the 2nd or later-line treatment of advanced solid tumors. PATIENTS AND METHODS: A total of 63 patients with advanced solid tumors who had failed or could not endure the adverse reactions aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shu-hui, Li, Yi-Wen, Li, Ying-Jue, Liu, Lin-Bo, Zhang, Qun, Lu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560472/
https://www.ncbi.nlm.nih.gov/pubmed/37814643
http://dx.doi.org/10.2147/IJGM.S426590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560472/
https://www.ncbi.nlm.nih.gov/pubmed/37814643
http://dx.doi.org/10.2147/IJGM.S426590

Ejemplares similares